China says it has given conditional approval for Pfizer’s COVID-19 drug Paxlovid to treat adults with mild to moderate illness and a high risk of developing severe disease. Pfizer says that preliminary studies show that Paxlovid does not target the ever-evolving spike protein the coronavirus uses to invade cells, meaning...
- Release Date:February 15, 2022
